Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 18/20 | 0.81 |
| ▸ | AKR1C2 | P52895 | 18/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293867 | 0.89 | AKR1C3 (1.00) | AKR1C3AKR1C2MAPT | |
| SCHEMBL846875 | 0.88 | AKR1C3 (0.81) | AKR1C3AKR1C2GAA | |
| SCHEMBL294128 | 0.87 | AKR1C3 (0.78) | AKR1C3AKR1C2 | |
| SCHEMBL16372498 | 0.86 | AKR1C3 (0.64) | AKR1C3AKR1C2MAPTALOX15GAA | |
| SCHEMBL296153 | 0.85 | AKR1C3 (0.76) | AKR1C3AKR1C2GAA | |
| SCHEMBL4215631 | 0.85 | AKR1C3 (0.65) | AKR1C3AKR1C2MAPT | |
| SCHEMBL8834052 | 0.85 | AKR1C3 (0.62) | AKR1C3AKR1C2MAPTALOX15GAA | |
| SCHEMBL902692 | 0.85 | AKR1C3 (0.64) | AKR1C3AKR1C2MAPTALOX15 | |
| SCHEMBL8529851 | 0.84 | MAPT (0.74) | AKR1C3AKR1C2MAPTALOX15GAA | |
| SCHEMBL27568225 | 0.84 | CTSV (0.58) | AKR1C3AKR1C2MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667685-B1 | QUINAZOLINE POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2012-03-14 | — | — | EP | disclosed |
| CN-101094829-B | novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO.,LTD. (JP) | 2012-02-08 | — | — | CN | disclosed |
| US-7906521-B2 | Quinazoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906521-B2 | Quinazoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906521-B2 | Quinazoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-1667685-A4 | QUINAZOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | disclosed |
| CN-101094829-A | Novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| US-20070054894-A1 | Quinazoline potassium channel inhibitors | MERCK & CO., INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054894-A1 | Quinazoline potassium channel inhibitors | MERCK & CO., INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054894-A1 | Quinazoline potassium channel inhibitors | MERCK & CO., INC. (US) | 2007-03-08 | — | — | US | disclosed |
| EP-1667685-A1 | QUINAZOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030217-A1 | QUINAZOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-6008213-A | A INHIBITOR OF VITRONECTIN RECEPTOR AND FIBRINOGEN RECEPTOR; USEFUL FOR INHIBITING PLATELET AGGREGATION AND OSTEOPOROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0910563-A4 | — | — | 1999-04-28 | — | — | EP | disclosed |
| EP-0910563-A1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997001540-A1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054894-A1 | Quinazoline potassium channel inhibitors | KCNJ2, KCNH2, KCNH3 | AKR1C3 2614/4885AKR1C2 1933/4885MAPT 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.